A structural domain binding to ALV reverse transcriptase RT, a vaccine and its use
By identifying and using the domains that bind to ALV reverse transcriptase RT, vaccines or drugs are prepared, and the problem of difficult prevention and treatment of avian leukemia virus is solved, broad-spectrum resistance to different subtypes of ALV is achieved, and virus proliferation is reduced. Provides effective prevention and control methods.
Patent Information
- Application Number
- CN202411002989.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-25
AI Technical Summary
The prior art has failed to effectively prevent and treat avian infectious diseases caused by avian leukemia virus (ALV). The traditional purification and control strategies take a long time, are labor-intensive and cost-effective, and there is no effective vaccine or drug available.
Identify the domain in which the eEF1A protein binds to ALV reverse transcriptase RT, prepare vaccines or drugs through this domain, inhibit or knock out the domain to block ALV virus replication, use siRNA to reduce eEF1A gene expression, and combine with precise gene editing and culture Highly resistant chickens that resist ALV.
It was clarified that the key function of eEF1A protein regulates viral replication by binding to ALV reverse transcriptase RT, and identified the key domain as potential anti-ALV molecular targets, achieving broad-spectrum resistance to different subtypes of ALV, reducing viral proliferation, and providing Effective methods for preventing and controlling avian leukemia.
Smart Images

Figure CN118546229B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of molecular biotechnology, and specifically relates to a structural domain combined with ALV reverse transcriptase RT, a vaccine and a use thereof. Background Art
[0002] Avian leukosis is an infectious disease of poultry caused by the avian leukosis virus (ALV), which causes malignant proliferation of hematopoietic cells. Under natural conditions, the disease mainly attacks bone marrow cells and organs such as the liver and spleen, causing various tumors such as myeloma and hemangioma, resulting in slow growth and decreased production performance in chickens, leading to severe immunosuppression and immune tolerance in sick chickens, causing significant economic losses to the poultry industry. According to the differences in the envelope protein of the avian leukosis virus and the host cells, ALV can be divided into 11 subgroups, AK, of which A, B, J, and K are common exogenous viruses, and E is an endogenous virus. So far, no vaccine or drug that can effectively prevent and treat this disease has been reported.
[0003] At present, the main measure to prevent and control avian leukosis is to purify the original breeder farms, screen out the infected chickens, and establish a core breeder flock free of ALV infection. However, this traditional purification control strategy takes a long time to purify, is labor-intensive, and expensive, and negative chickens are still at risk of reinfection with ALV. Establishing a breeder flock free of avian leukosis through disease-resistant breeding methods is another important and effective measure to prevent and control avian leukosis. Therefore, based on the ALV life cycle, it is of great significance to identify the common disease-resistant genes and key amino acid sites of multi-subtype ALV, and provide operable gene editing targets for breeding highly resistant chickens with special resistance to multi-subtype ALV.
[0004] Eukaryotic Elongation Factor 1 Alpha (eEF1A) is one of the most widely distributed and abundant proteins in eukaryotic cells. In normal cells, the total amount of protein is second only to actin, accounting for about 1% to 3% of the total. The eEF1A protein, together with the eEF1B complex (eEF1B, eEF1D and eEF1G) and valyl-tRNA, constitute the eukaryotic translation elongation complex (eEF1), which performs the ribosomal translation elongation function. In addition to its typical functions, the eEF1A protein is also involved in many non-typical functions such as protein degradation, nucleocytoplasmic transport, heat shock response, apoptosis and cytoskeleton regulation, emphasizing its importance in different cellular processes. In addition, eEF1A plays a regulatory role in the infection process of various viruses. It can affect viral proliferation and pathogenicity by binding to viral proteins or viral genomes, but there is no report on the effect of the domain binding to ALV reverse transcriptase RT on ALV virus. Summary of the invention
[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides a domain on the eEF1A protein that binds to ALV reverse transcriptase RT, a vaccine and uses. The present invention clarifies that eEF1A has the key function of regulating viral replication by binding to ALV reverse transcriptase RT, and further identifies the key domain of eEF1A binding to ALV reverse transcriptase RT, indicating that the key domain of eEF1A is a potential molecular target against ALV.
[0006] To achieve the above purpose, the technical solution adopted by the present invention to solve the technical problem is:
[0007] The domain on the eEF1A protein that binds to ALV reverse transcriptase RT has an amino acid sequence of VGEFEAGISKNGQTRE (SEQ ID NO.1).
[0008] Furthermore, it consists of amino acids 120 to 135 of the eEF1A protein.
[0009] Furthermore, the loss of this domain will cause the ALV virus to lose its ability to replicate.
[0010] The use of the above structural domain in preparing drugs for preventing and treating ALV virus.
[0011] Furthermore, the drug contains an active ingredient that inhibits / knocks out the domain, or silences / inhibits the expression of the eEF1A gene.
[0012] Furthermore, the active ingredient is siRNA, and its nucleotide sequence is: CCAAAUCAGUGCUGGUUAUTT.
[0013] A vaccine comprising the above-mentioned domain.
[0014] The use of the above-mentioned domain in breeding ALV-resistant varieties.
[0015] The use of the above domain in screening ALV-resistant varieties.
[0016] Beneficial effects of the present invention:
[0017] The present invention clarifies that eEF1A has the key function of regulating viral replication by binding to ALV reverse transcriptase RT, and further identifies the key domain of eEF1A binding to ALV reverse transcriptase RT, indicating that the key domain of eEF1A is a potential molecular target for anti-ALV. In this way, the application of specific domains and sites of eEF1A in the prevention and control of ALV can be explored, that is, new transgenic chicken materials with broad-spectrum resistance to different subtypes of ALV can be obtained through precise gene editing. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1Figure 1 is a graph showing the effect of eEF1A protein on ALV replication; Figure A is a graph showing the p27 antigen content in cells infected with ALV-J SCAU1903; Figure B is a graph showing the p27 antigen content in cells infected with different subtypes of ALV;
[0019] Figure 2 This is a diagram for detecting the direct interaction between eEF1A protein and ALV reverse transcriptase RT;
[0020] Figure 3 This is the Autodock analysis diagram of eEF1A protein and ALV reverse transcriptase RT;
[0021] Figure 4 This is a diagram showing the effect of the key domains of the eEF1A protein on the interaction between eEF1A and ALV reverse transcriptase RT;
[0022] Figure 5 Figure 5 is a graph showing the detection of siRNA knockout efficiency; Figure A is a graph showing the detection of siRNA knockout efficiency by Western Blot; Figure B is a graph showing the detection of siRNA knockout efficiency by fluorescent quantitative PCR; and Figure C is a graph showing the effect of siRNA on cell proliferation activity. DETAILED DESCRIPTION
[0023] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.
[0024] Example 1: Effect of eEF1A protein on ALV replication
[0025] 1. An effective siRNA sequence (Sense: 5'-CCAAAUCAGUGCUGGUUAUTT-3') was designed and verified based on the chicken eEF1A gene sequence (NCBI accession number: 373963).
[0026] 2. DF-1 cells were transfected with siRNA using the Thermo Fisher lip3000 transfection kit. After 24 h, ALV-J SCAU1903 was infected at an MOI of 1. Cell supernatant samples were collected for 5 consecutive days. The p27 antigen content in the samples was detected using the ALV antigen detection ELISA kit of Guosheng Biotechnology ( Figure 1 Middle A) and knockout efficiency ( Figure 5). The results showed that after siRNA treatment, the levels of eEF1A gene and p27 antigen in the cell supernatant were significantly reduced, indicating that knocking down the expression level of eEF1A could inhibit the proliferation of ALV-JSCAU1903.
[0027] 3. siRNA was transfected into DF-1 cells using the Thermo Fisher Scientific lip3000 transfection kit. After 24 h, different subtypes of ALV (ALV-A GD08, ALV-B SDAU09C2 and ALV-K JS11C1) were infected at an MOI of 1. The cell supernatant samples were collected and the p27 antigen content in the samples was detected using the ALV antigen detection ELISA kit of Guosheng Biotechnology.
[0028] The results are as follows Figure 1 As shown in Figure B, after siRNA treatment, the proliferation levels of different subtypes of ALV were significantly inhibited, indicating that knocking down the expression level of eEF1A has a broad-spectrum inhibitory effect on the proliferation of different subtypes of ALV.
[0029] Example 2 Direct interaction between eEF1A protein and ALV reverse transcriptase RT
[0030] 1. Construction of eEF1A recombinant plasmid
[0031] (1) Using the cDNA of the eEF1A gene of DF-1 cells as a template, specific primers F1 / R1 with homology arms were designed to amplify the full-length CDS sequence of eEF1A;
[0032] (2) Using the mCherry-N1 vector as a template, amplify the mCherry linearized vector using specific primers F2 / R2;
[0033] (3) Use the homologous recombination kit of Novozymes to connect the above two fragments, and the ligation product is transferred into Escherichia coli DH5α competent cells and cultured at 37°C overnight;
[0034] (4) Use universal primers F3 / R3 to perform PCR amplification and sequencing of single clones, and extract plasmids from correct transformants for use.
[0035] 2. Construction of reverse transcriptase RT recombinant plasmid
[0036] (1) Using ALV-J SCAU1903 proviral genomic DNA as a template, specific primers F4 / R4 with homology arms were designed to amplify the full-length sequence of ALV-J reverse transcriptase RT;
[0037] (2) Using EGFP-C1 vector as template, amplify the EGFP linearized vector using specific primers F5 / R5;
[0038] (3) Use the homologous recombination kit of Novozymes to connect the above two fragments, and the ligation product is transferred into Escherichia coli DH5α competent cells and cultured at 37°C overnight;
[0039] (4) Use universal primers F6 / R6 to perform PCR amplification and sequencing of single clones, and extract plasmids from correct transformants for use.
[0040] Table 1 Primers
[0041]
[0042] 3. Transfection co-localization
[0043] The constructed eEF1A recombinant plasmid and reverse transcriptase RT recombinant plasmid were transformed into DF-1 cells using the Thermo Fisher Lip3000 transfection kit. After 48 h, the protein co-localization was observed using a Leica laser confocal microscope. The results are shown in Figure 2 .
[0044] like Figure 2 As shown, mCherry-eEF1A and EGFP-RT were clearly co-localized, proving the direct interaction between eEF1A protein and ALV reverse transcriptase RT.
[0045] Example 3 Autodock analysis of eEF1A protein and ALV reverse transcriptase RT
[0046] The molecular models of host protein eEF1A and ALV-J reverse transcriptase RT were calculated by homology modeling using the SWISS-MODEL server (https: / / swissmodel.expasy.org / ). The specific process is as follows:
[0047] The molecular docking of ALV-J RT with eEF1A protein was performed using the ClusPro server (https: / / cluspro.bu.edu / ), and the predicted eEF1A and ALV-J RT prediction models were used for docking simulations. During the docking process, eEF1A was set as the receptor and ALV-J RT was set as the ligand. The ligand was rotated 70,000 times. For each rotation, the ligand was translated on the grid relative to the x, y, and z axes of the receptor, and the best-scoring result was selected from each rotation. Among the 70,000 rotations, this protocol selected the 1,000 rotation / translation combinations with the lowest scores. Then, these 1,000 ligand positions were clustered using a 9 Å C-alphaRMSD radius to find the ligand position with the most "adjacent" ligands within 9 Å, i.e., the cluster center. Finally, the top 10 cluster centers with the most retrieved cluster members were visually inspected one by one, and the most likely form of molecular contacts was further evaluated. The generation of the docking model molecular graphics was edited using PyMOL software, and the results are shown in Figure 3 .
[0048] like Figure 3 As shown, a total of 20 hydrogen bonds and 6 salt bridge interactions were formed between eEF1A and ALV-J reverse transcriptase RT. The amino acid regions where eEF1A binds to RT are mainly concentrated in two parts: 17-56 AA and 120-135 AA, while the amino acid region where ALV-JRT binds to eEF1A is mainly concentrated in 245-395 AA.
[0049] Example 4 Effect of the key domain of eEF1A protein on the interaction between eEF1A and ALV reverse transcriptase RT
[0050] 1. Construction of plasmids with lost key domains of eEF1A protein
[0051] Using the full-length cDNA amplification product of eEF1A as a template, specific primers with homology arms were designed to amplify the eEF1A amino acid 1-56 deletion fragment (primer pair F1 / R1 in Table 2 ), amino acid 120-135 deletion fragment (primer pair F2 / R2 in Table 2 ), and amino acid 1-135 deletion fragment (primer pair F3 / R3 in Table 2 ), and the eukaryotic expression vector pRK5-HA was linearized using vector-specific primers (primer pair F4 / R4 in Table 2 ).
[0052] The amino acid deletion fragments of the eEF1A protein were recombined and connected with the linearized vector using the homologous recombination kit of Novagen, and transformed into Escherichia coli DH5α competent cells. After overnight culture at 37°C, single clones were amplified and sequenced by PCR, and plasmids were extracted from correct transformants for use.
[0053] Table 2 Primers for construction of eEF1A domain-deficient plasmid
[0054]
[0055] 2. Transfect cells
[0056] The relevant plasmid vectors were transferred into DF-1 cells using the Thermo Fisher Lip3000 transfection kit. Cell proteins were collected 48 h later and protein samples were enriched using HA immunomagnetic beads from MedChemExpress. The cells were incubated overnight at 4°C and protein expression was detected by Western Blot. The results are shown in Figure 4 .
[0057] like Figure 4 As shown, after the deletion of amino acids 120-135 of eEF1A, eEF1A lost the ability to bind to reverse transcriptase RT, indicating that the amino acid domain 120-135 of eEF1A plays a key role in the interaction between eEF1A and reverse transcriptase RT.
[0058] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to examples, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.
Claims
1. A domain on the eEF1A protein that binds to ALV reverse transcriptase RT, characterized in that: The amino acid sequence of the domain is shown in SEQ ID NO.
1.
2. The domain according to claim 1, characterized in that It is composed of amino acids 120 to 135 of the eEF1A protein.
3. The domain according to claim 1, characterized in that The loss of this domain will cause the ALV virus to lose its ability to replicate.
4. Use of siRNA for silencing / inhibiting eEF1A gene expression in the preparation of a drug for preventing and treating ALV virus, characterized in that: Its nucleotide sequence is: CCAAAUCAGUGCUGGUUAUTT.
Citation Information
Patent Citations
Protein capable of inhibiting release of virus particles, coding sequence of protein and application in inhibiting release of retrovirus from cells
CN103073629A
Identification and application of ALV-J MHC-B2 restrictive epitope peptide
CN114349829A
Mammalian genes involved in infection
WO2011008956A2
